Global Companion Diagnostics Market Outlook 2030

  • Product Code:
    RP-ID-10059273
  • Published Date:
    16 Sep 2021
  • Region:
    Global
  • Pages:
    138
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-12

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

ccs

Market Overview:

" The global companion diagnostics market generated a revenue of USD ~2.5 billion in 2021 and is expected to expand at a compound annual growth rate of ~21% over the period 2022-2030. Companion diagnosis is an in vitro medical device that provides essential information for the safe and effective use of corresponding drugs or biological products. This diagnostic test can help healthcare professionals determine whether a particular treatment product is beneficial to the patient and whether it can overcome potential side effects or serious risks.Due to the increase in the research and development of targeted therapies, the increased awareness of emerging economies for personalized medicine, the discovery of new biomarkers for various diseases, and the increase in the demand for cancer treatment, it is expected that the auxiliary diagnosis market will show signs of Is growing. Promote the growth of the global auxiliary diagnostic market.

 

COMPANION DIAGNOSTICS MARKET SEGMENTATION:


The global auxiliary diagnosis market is segmented by technology type, indication and region. According to the type of technology, the market is divided into immunohistochemistry, polymerase chain reaction (PCR), next generation sequencing (NGS), in situ hybridization, etc. According to indications, the market is divided into oncology, neurology, etc.Oncology is further subdivided into lung cancer, colorectal cancer, breast cancer, blood cancer, etc. Depending on the region, the market has been studied in North America (the United States, Canada, and Mexico), Europe (Germany, France, the United Kingdom, and the rest of Europe), and the Asia-Pacific region (China, Japan, Australia, and the rest of Asia). Pacific) and LAMEA (Brazil, South Africa and the rest of LAMEA).

 

MARKET SEGMENT REVIEW :


Based on technology, the PCR segment dominates the global market, and this trend is expected to continue during the forecast period. Some of the key factors driving market growth are profitability, high sensitivity and specificity, which can be used in simple automation platforms. In addition, the sequencing of unknown causes of many diseases can be confirmed by PCR, which is another key factor in this field.

 

However, the next-generation sequencing segment is expected to grow rapidly during the forecast period, as its key advantages include higher sensitivity for detecting low-frequency variants, shorter response time to large sample sizes, and the ability to perform analysis on hundreds or thousands of genes. At the same time, sequencing or gene regions are waiting, mainly to promote the growth of the market. Oncomine Dx Target Test, FoundationOne CDx, FoundationFocus CDxBRCA Assay, etc. use next-generation sequencing for detection.

 

According to the signs, the global auxiliary diagnosis market is segmented into oncology, neurology, etc. Currently, the oncology department is the department with the highest revenue and is expected to see significant growth during the forecast period.

 

Some key factors, such as the high prevalence of cancer, the increase in the number of cancer research and development activities, the increase in the number of unmet needs for cancer treatment, the increase in the number of supplementary diagnostics approved by the FDA, and the increase in patient awareness. The main driving force for personalized medicine is oncology . The growth of the academic field.

 

Cancer research has identified significant differences in gene sequences and expression patterns, which may be the basis for targeted therapy. In addition, many biomarkers have been identified for different cancers and supplementary diagnoses have been made for these cancers. Supplementary diagnosis is widely used in different forms of cancer, such as lung cancer, colorectal cancer, breast cancer, and blood cancer, which are the main causes of death. The market share of breast cancer assisted diagnosis is higher because there are many assisted diagnoses developed to detect breast cancer mutations; the target population is large.

 

OVERVIEW OF THE ASSISTED DIAGNOSIS MARKET IN THE ASIA PACFIC REGION:


The Asia-Pacific region provides profitable opportunities for major players in the assisted diagnosis market because of the high population base, increased awareness of assisted diagnosis, development of health infrastructure, and increased demand for treatment advancement. However, the higher R&D costs incurred by the development of additional diagnostics may hinder the growth of the additional diagnostics market in the Asia-Pacific region.

 

THE MAIN PARTICIPANTS :


Described in this report include Abbott Laboratories Molecular, Inc., Agilent (Dako Denmark A/S), ARUP Laboratories, Inc., BioMerieux SA, Danaher Corporation (Leica Microsystems), Foundation Medicine, Inc., Myriad Genetics, Inc.. , Qiagen NV, Roche (Ventana Medical Systems, Inc.) and Thermo Fisher Scientific (Life Technologies Corporation).The main benefits of the auxiliary diagnostics market: The study provides an in-depth analysis of the auxiliary diagnostics market size and current trends and future estimates to clarify the upcoming investment pockets. Provides a quantitative analysis from 2022-2030, which is expected to enable stakeholders to take advantage of current market opportunities to provide a comprehensive supplementary diagnostic market analysis of all regions to determine current opportunities. Key players’ growth profiles and strategies are thoroughly analyzed to understand Competitive prospects in the global market.

 

Companion diagnostics key market Segments:

 

By technology type Immunohistochemistry Polymerase chain reaction (PCR) Next generation sequencing (NGS) In situ hybridization Others By indication Oncology Neurology Others. "


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

.

FREQUENTLY ASKED QUESTIONS

1 INTRODUCTION OF GLOBAL COMPANION DIAGNOSTICS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER
5.1 Pharma and Biotech Companies
5.2 Reference Laboratories
5.3 Others

6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION
6.1 Oncology
6.1.1 Breast Cancer
6.1.2 Lung Cancer
6.1.3 Colorectal Cancer
6.1.4 Melanoma
6.1.5 Gastric Cancer
6.1.6 Other Cancers Toiletries
6.2 Neurology
6.3 Infectious diseases
6.4 Other indications

7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES
7.1 Assay Kits and Reagents
7.2 Software & Services

8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 – 2025

9 GLOBAL COMPANION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 F. Hoffmann-La Roche AG
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Agilent Technologies, Inc.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Qiagen N.V.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Thermo Fisher Scientific Inc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Abbott Laboratories, Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Biomerieux SA
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Danaher Corporation
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Illumina, Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Myriad Genetics, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Arup Laboratories Inc.
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Sysmex Corporation
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments
10.12 Hologic Inc.
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 Novartis AG
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

10.14 Almac Group
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Developments

10.15 Abnova Corporation
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Developments

11 Appendix
11.1 Related Reports

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports